Cellectar Biosciences, Inc.
CLRB
$0.2515
$0.00732.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 83.94% | -1,495.03% | 96.55% | -238.05% | 55.02% |
| Total Depreciation and Amortization | 0.00% | 3.94% | -25.42% | 26.43% | 69.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -367.13% | 127.54% | -175.44% | 558.17% | -138.84% |
| Change in Net Operating Assets | -102.86% | 234.97% | 26.40% | -241.37% | 113.79% |
| Cash from Operations | -19.05% | 35.18% | -5.83% | -39.25% | -18.94% |
| Capital Expenditure | -- | 100.00% | 1.39% | 91.90% | 55.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 1.39% | 91.90% | 55.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -100.00% | 9,843.20% | -98.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -- | -100.00% | 9,843.20% | -98.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -230.74% | 159.27% | -146.49% | 423.37% | -168.11% |